| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8245077 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 6 Pages |
Abstract
Conclusion: Three-course 80%-CHOP followed by involved-field radiotherapy may be safe for administration to elderly patients over 70 years old. The next step is to evaluate three-course 80%-CHOP and rituximab followed by radiotherapy in elderly patients with localized disease.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Naoto M.D., Masahiko M.D., Koichi M.D., Katsumasa M.D., Yoshio M.D., Masatoshi M.D., Takeshi M.D., Shigeru M.D., Yoshikazu M.D., Japan Radiation Oncology Group (JAROG) Japan Radiation Oncology Group (JAROG),